ResearcherSpanish National Cancer Research CentreActive in the last 2 years
Mónica P. de Andrés
Matched on ORCID iD 0000-0003-4654-7020; OpenAlex author ID A5051906316. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper
Papers 3
- GATA4 loss promotes mutant Kras -driven pancreatic ductal adenocarcinoma in the absence of canonical precursor lesions First author DOI 10.64898/2026.05.22.724502↗
- GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325803↗
- Mutant Kras Dosage and Chromothripsis: The Right Ingredients for a Pancreatic Cancer Catastrophe. First author DOI 10.1016/j.trecan.2018.04.004↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Francisco X. Real · 3 shared papers, 2018–2026 · strength 0.55
- Paper GATA4 loss promotes mutant Kras -driven pancreatic ductal adenocarcinoma in the absence of canonical precursor lesions DOI 10.64898/2026.05.22.724502↗
- Paper Mutant Kras Dosage and Chromothripsis: The Right Ingredients for a Pancreatic Cancer Catastrophe. DOI 10.1016/j.trecan.2018.04.004↗
- Paper GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancrea… DOI 10.1136/gutjnl-2021-325803↗
- Paola Martinelli · 2 shared papers, 2023–2026 · strength 0.37
- Paper GATA4 loss promotes mutant Kras -driven pancreatic ductal adenocarcinoma in the absence of canonical precursor lesions DOI 10.64898/2026.05.22.724502↗
- Paper GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancrea… DOI 10.1136/gutjnl-2021-325803↗
- Francesc Madriles · 1 shared paper, 2026 · strength 0.24
- Scott W. Lowe · 1 shared paper, 2026 · strength 0.24
- Iréne Esposito · 1 shared paper, 2026 · strength 0.24
- Juan Iovanna · 1 shared paper, 2026 · strength 0.24
- Wilko Weichert · 1 shared paper, 2023 · strength 0.13
- Sladjana Zagorac · 1 shared paper, 2023 · strength 0.13
- Anna Melissa Schlitter · 1 shared paper, 2023 · strength 0.13
- Irene Felipe‐Abrio · 1 shared paper, 2023 · strength 0.13
- Thomas Knösel · 1 shared paper, 2023 · strength 0.13
- Paula Ghaneh · 1 shared paper, 2023 · strength 0.13
- Daniel H. Palmer · 1 shared paper, 2023 · strength 0.13
- Thilo Hackert · 1 shared paper, 2023 · strength 0.13
- Núria Malats · 1 shared paper, 2023 · strength 0.13
- John P. Neoptolemos · 1 shared paper, 2023 · strength 0.13
- William Greenhalf · 1 shared paper, 2023 · strength 0.13
- Steve Gallinger · 1 shared paper, 2023 · strength 0.13
- Faiyaz Notta · 1 shared paper, 2023 · strength 0.13
- Christian P. Pilarsky · 1 shared paper, 2023 · strength 0.13
- Eithne Costello · 1 shared paper, 2023 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.